News | Intra-Vascular Ultrasound (IVUS) | March 13, 2018

Infraredx Highlights Value of IVUS + NIRS for Detecting Lipid Core Plaque at ACC.18

Presentation bolsters company’s upcoming studies in IVUS + NIRS imaging including its highly-anticipated PROSPECT II and Lipid-Rich Plaque Study findings  

Infraredx Highlights Value of IVUS + NIRS for Detecting Lipid Core Plaque at ACC.18

March 13, 2018 –  Infraredx, a company that works in intravascular imaging for mapping coronary artery disease, today presented a poster at the American College of Cardiology (ACC) 67th Annual Scientific Session supporting the value of combination intravascular ultrasound (IVUS) and near-infrared spectroscopy (NIRS) imaging technology to identify lipid core plaque (LCP), an underlying cause of serious cardiac events. In the poster presentation, IVUS +NIRS demonstrated efficiencies in locating LCP within arteries, indicating the technology may be a better predictor of major adverse cardiac events (MACE) than the current methodology standard set forth by the PROSPECT study.

“This analysis validates the use of dual-modality IVUS + NIRS catheters to clearly pinpoint LCP with increased efficiency compared to IVUS alone,” said Jason Bottiglieri, president and CEO of Infraredx. “Unlike other imaging technologies, NIRS can readily distinguish areas of stable plaque from potentially dangerous LCP, which may enable cardiologists to more accurately predict and ultimately prevent serious heart attacks.”

At ACC, March 10-12, 2018, Infraredx presented Poster #241: A Correlative Study of NIRS Lipid Core Burden Index Versus Histological Plaque Disease Arc in Human Coronary Autopsy Specimens.

Study Methodology and Results

  • The PROSPECT Study found in a sub-study that the plaque disease arc via transverse IVUS was an additional independent predictor of non-culprit lesion of MACE. However, the area under the curve (AUC) parameter that was observed in the study was low (0.64) and the methodology only included use of gray-scale IVUS. 
  • Infraredx utilized a similar disease arc concept in an IVUS + NIRS autopsy study to reveal the benefits and limitations of the disease arc concept. Since underlying pathological truths can be known in an autopsy study, the degree to which disease arc finds lipid core plaques could be studied, as well as novel methods incorporating the unique IVUS + NIRS chemogram map of vessel lipid core could also be explored.
  • The study concluded that quickly locating areas of LCP with NIRS, and then assessing the disease arc on IVUS cross-sections of interest may be more targeted than use of the IVUS disease arc alone. It also may be more clinically efficient due to the automated and immediate generation of the NIRS chemogram.

“PROSPECT demonstrated that vulnerable plaques can be detected with IVUS technology, but with only modest predictive ability,” said Gregg Stone, M.D., Columbia University Medical Center and New York-Presbyterian Hospital. “As demonstrated in this study, NIRS offers the potential to further discriminate plaques, which are likely to be particularly high-risk such as those with high lipid content, a hypothesis that is being tested in ongoing PROSPECT II and LRP studies.”

For more information:

Related Content

A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.

Feature | ACC | March 27, 2018 | Dave Fornell
There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American Colle
Drug Stops Dangerous Bleeding in Patients Taking Factor Xa Inhibitors


News | ACC | March 22, 2018
March 22, 2018 — The experimental drug...
Videos | ACC | March 21, 2018
DAIC Editor Dave Fornell takes a tour of some of the most interesting new technologies on the expo floor at
ACC 2018 Late-Breaking Trials Announced
News | ACC | March 21, 2018
Here is a list of the American College of Cardiology (ACC) 2018 annual meeting late-breaking clinical trials presente
Inhaled Therapy Ineffective in Difficult-to-Treat Heart Failure at ACC 2018.

Image from presentation, "Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF: The INDIE-HFpEF Trial," Borlaug

News | ACC | March 20, 2018
March 20, 2018 — Four weeks of treatment with a novel inhaled medication failed to improve exercise capacity, daily a
More Deaths, Strokes Seen with Perioperative Beta Blocker One Year After Surgery

Image from presentation, "1-Year outcomes of perioperative beta-blockade in patients undergoing noncardiac surgery," Devereaux 

News | ACC | March 20, 2018
March 20, 2018 — During the 12 months after undergoing noncardiac surgery, patients with or at risk for heart disease
Trial for Gout Drug Meets Primary Endpoint, Raises Safety Concerns, image shows a CT scan showing gout in the knees.
News | ACC | March 20, 2018
March 20, 2018 — Febuxostat, a gout dr...
Canakinumab Doesn’t Prevent Prediabetes from Progressing to Diabetes according to a late-breaking study at ACC 2018.
News | ACC | March 20, 2018
March 20, 2018 — The anti-inflammatory...
Dabigatran Reduces Major Cardiovascular Complications in Patients With Myocardial Injury after Noncardiac Surgery
News | ACC | March 20, 2018
March 20, 2018 — Treatment with the blood-thinning drug dabigatran significantly reduced the risk of death, heart att
Statins May Bring Benefits at Time of Treatment for Heart Attack, Angina

Image from presentation, "Statins Evaluation in Coronary Procedures and Revascularization," Berwanger 

News | ACC | March 20, 2018
March 20, 2018 — Getting a large dose of a statin did not have an impact on major adverse cardiac events among a broa
Overlay Init